Fibroblast growth factor receptor 3 (FGFR3) binding proteins

US8187601B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Zhigang Weng · Cambridge, US
• William M. Winston, Jr. · Marlborough, US
• Lyne Breault · Brookline, US
• Kristan Meetze · Lexington, US
• Solly Weiler · Newton, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Jun 30, 2009
• Grant date: May 29, 2012
• Expiry date: Apr 10, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3.